Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 384 Cr.
- Current Price ₹ 813
- High / Low ₹ 956 / 635
- Stock P/E 19.5
- Book Value ₹ 299
- Dividend Yield 0.09 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.68 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 456 | |
| 401 | |
| Operating Profit | 55 |
| OPM % | 12% |
| 0 | |
| Interest | 22 |
| Depreciation | 5 |
| Profit before tax | 27 |
| Tax % | 28% |
| 20 | |
| EPS in Rs | 41.81 |
| Dividend Payout % | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 5% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | 5 |
| Reserves | 137 |
| 167 | |
| 179 | |
| Total Liabilities | 487 |
| 53 | |
| CWIP | 0 |
| Investments | 2 |
| 433 | |
| Total Assets | 487 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -29 | |
| -6 | |
| 39 | |
| Net Cash Flow | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 142 |
| Inventory Days | 265 |
| Days Payable | 160 |
| Cash Conversion Cycle | 247 |
| Working Capital Days | 202 |
| ROCE % |
Documents
Announcements
-
Investors Presentation Issued By Fredun Pharmaceuticals Limited Stating Annual Review & Strategic Outlook For Growth In The Pharma Industry
10 Jun - Fredun Pharmaceuticals' June 2025 investor presentation on annual review, growth strategy, and product expansions.
- Investor Presentation Of Fredun Pharmaceuticals Limited 10 Jun
-
Revised Outcome Of The Board Meeting Dated 30.05.2025
31 May - Fredun Pharma reports FY25 audited results; net profit Rs 2080.76L, recommends 7% final dividend.
-
Standalone And Consolidated Audited Financial Results For The Quarter And Financial Year Ended March 31, 2025 Along With Statement Of Assets And Liabilities And Cash Flow Statement
31 May - Fredun Pharma reports FY25 audited results; net profit Rs 2080.76L; recommends 7% final dividend.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
31 May - Fredun reports 30.7% revenue growth, new veterinary products, international petcare launch, and Rs. 150-180 mn tender win.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company is a subsidiary of Fredun Group. It manufactures pharmaceutical and allopathic formulations viz. tablets, syrups, capsules, and ointments. Product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral and anti-hypertensive. Company also ventured into manufacturing of dietary/herbal supplements, neutraceuticals, diagnostic kits along with Animal Healthcare products through its group companies Fredun Healthcare Pvt. Ltd. & Fredna Entereprises.
Company has 23 therapeutic classes*(including anti-diabetics, anti-retroviral
and anti-hypertensive), with 450** products registered in overseas markets.